Pandorum Technologies, a Bangalore, India-based biotechnology company, raised $11M in funding.
Backers included Mr. Ashish Kacholia, Everest Finance Investment, Acebright Pharma and Ms. Bandana Kankani’s syndicate, along with existing investors Mr. Sunil Kant Munjal and the Indian Angel Network.
The company intends to use the funds to expand operations and its R&D efforts.
Founded by Arun Chandru & Dr. Tuhin Bhowmick, Pandorum Technology is a tissue engineering and regenerative medicine company that uses the foundational and translational principles of biology and engineering to design therapeutic products, that aim to alleviate the health conditions of patient’s suffering from on corneal dystrophies, lung related disorders and liver diseases. Pandorum also has capabilities in building 3D functional tissues through a combination of cells, gels, and cell modulators, using self-assembly, 3D printing, and other fabrication methods to construct desired tissue like micro-architecture. Its proprietary technology platform is designed to develop functional human tissues, such as bio-engineered Cornea and Liver, intended for medical research and therapeutic applications.
Commenting on the news, Tuhin Bhowmick said: “We are thrilled to have the support of the notable investors, including Mr. Ashish Kacholia- as we continue to innovate and develop therapeutics to restore healthy tissue functions, in order to help the patients suffering from unmet clinical needs. Our flagship product Kuragenx combines proprietary biomaterials with regenerative nanotherapy, guiding the formation of a functional corneal tissue to restore vision. This is a First-in-Class approach that can truly blur the line between treatment and cure.”
FinSMEs
18/03/2024